The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variants

The constant mutation of SARS-CoV-2 has led to the continuous appearance of viral variants and their pandemics and has improved the development of vaccines with a broad spectrum of antigens to curb the spread of the virus. The work described here suggested a novel vaccine with a virus-like structure...

Full description

Saved in:
Bibliographic Details
Main Authors: Jingjing Zhang, Fengyuan Zeng, Yanmei Li, Changyong Mu, Change Liu, Lichun Wang, Xiaowu Peng, Liping He, Yanrui Su, Hongbing Li, An Wang, Lin Feng, Dongxiu Gao, Zhixiao Zhang, Gang Xu, Yixuan Wang, Rong Yue, Junbo Si, Lichun Zheng, Xiong Zhang, Fuyun He, Hongkun Yi, Zhongshu Tang, Gaocan Li, Kaili Ma, Qihan Li
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2025.2473183
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849326077767319552
author Jingjing Zhang
Fengyuan Zeng
Yanmei Li
Changyong Mu
Change Liu
Lichun Wang
Xiaowu Peng
Liping He
Yanrui Su
Hongbing Li
An Wang
Lin Feng
Dongxiu Gao
Zhixiao Zhang
Gang Xu
Yixuan Wang
Rong Yue
Junbo Si
Lichun Zheng
Xiong Zhang
Fuyun He
Hongkun Yi
Zhongshu Tang
Gaocan Li
Kaili Ma
Qihan Li
author_facet Jingjing Zhang
Fengyuan Zeng
Yanmei Li
Changyong Mu
Change Liu
Lichun Wang
Xiaowu Peng
Liping He
Yanrui Su
Hongbing Li
An Wang
Lin Feng
Dongxiu Gao
Zhixiao Zhang
Gang Xu
Yixuan Wang
Rong Yue
Junbo Si
Lichun Zheng
Xiong Zhang
Fuyun He
Hongkun Yi
Zhongshu Tang
Gaocan Li
Kaili Ma
Qihan Li
author_sort Jingjing Zhang
collection DOAJ
description The constant mutation of SARS-CoV-2 has led to the continuous appearance of viral variants and their pandemics and has improved the development of vaccines with a broad spectrum of antigens to curb the spread of the virus. The work described here suggested a novel vaccine with a virus-like structure (VLS) composed of combined mRNA and protein that is capable of stimulating the immune system in a manner similar to that of viral infection. This VLS vaccine is characterized by its ability to specifically target dendritic cells and/or macrophages through S1 protein recognition of the DC-SIGN receptor in cells, which leads to direct mRNA delivery to these innate immune cells for activation of robust immunity with a broad spectrum of neutralizing antibodies and immune protective capacity against variants. Research on its composition characteristics and structural features has suggested its druggability. Compared with the current mRNA vaccine, the VLS vaccine was identified as having no cytotoxicity at its effective application dosage, while the results of safety observations in animals revealed fewer adverse reactions during immunization.
format Article
id doaj-art-c9b633e7bf1e40a7bee3e122b70d7cb6
institution Kabale University
issn 2164-5515
2164-554X
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Human Vaccines & Immunotherapeutics
spelling doaj-art-c9b633e7bf1e40a7bee3e122b70d7cb62025-08-20T03:48:14ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2025.2473183The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variantsJingjing Zhang0Fengyuan Zeng1Yanmei Li2Changyong Mu3Change Liu4Lichun Wang5Xiaowu Peng6Liping He7Yanrui Su8Hongbing Li9An Wang10Lin Feng11Dongxiu Gao12Zhixiao Zhang13Gang Xu14Yixuan Wang15Rong Yue16Junbo Si17Lichun Zheng18Xiong Zhang19Fuyun He20Hongkun Yi21Zhongshu Tang22Gaocan Li23Kaili Ma24Qihan Li25Weirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaWeirui Biotechnology (Kunming) Co. Ltd, Ciba Biotechnology Innovation Center, Kunming, Yunnan, ChinaThe constant mutation of SARS-CoV-2 has led to the continuous appearance of viral variants and their pandemics and has improved the development of vaccines with a broad spectrum of antigens to curb the spread of the virus. The work described here suggested a novel vaccine with a virus-like structure (VLS) composed of combined mRNA and protein that is capable of stimulating the immune system in a manner similar to that of viral infection. This VLS vaccine is characterized by its ability to specifically target dendritic cells and/or macrophages through S1 protein recognition of the DC-SIGN receptor in cells, which leads to direct mRNA delivery to these innate immune cells for activation of robust immunity with a broad spectrum of neutralizing antibodies and immune protective capacity against variants. Research on its composition characteristics and structural features has suggested its druggability. Compared with the current mRNA vaccine, the VLS vaccine was identified as having no cytotoxicity at its effective application dosage, while the results of safety observations in animals revealed fewer adverse reactions during immunization.https://www.tandfonline.com/doi/10.1080/21645515.2025.2473183Virus-like structureimmunitymRNA vaccinedosage
spellingShingle Jingjing Zhang
Fengyuan Zeng
Yanmei Li
Changyong Mu
Change Liu
Lichun Wang
Xiaowu Peng
Liping He
Yanrui Su
Hongbing Li
An Wang
Lin Feng
Dongxiu Gao
Zhixiao Zhang
Gang Xu
Yixuan Wang
Rong Yue
Junbo Si
Lichun Zheng
Xiong Zhang
Fuyun He
Hongkun Yi
Zhongshu Tang
Gaocan Li
Kaili Ma
Qihan Li
The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variants
Human Vaccines & Immunotherapeutics
Virus-like structure
immunity
mRNA vaccine
dosage
title The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variants
title_full The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variants
title_fullStr The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variants
title_full_unstemmed The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variants
title_short The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variants
title_sort characterization of technical design of a virus like structure vls nanodelivery system as vaccine candidate against sars cov 2 variants
topic Virus-like structure
immunity
mRNA vaccine
dosage
url https://www.tandfonline.com/doi/10.1080/21645515.2025.2473183
work_keys_str_mv AT jingjingzhang thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT fengyuanzeng thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT yanmeili thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT changyongmu thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT changeliu thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT lichunwang thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT xiaowupeng thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT lipinghe thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT yanruisu thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT hongbingli thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT anwang thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT linfeng thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT dongxiugao thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT zhixiaozhang thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT gangxu thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT yixuanwang thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT rongyue thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT junbosi thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT lichunzheng thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT xiongzhang thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT fuyunhe thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT hongkunyi thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT zhongshutang thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT gaocanli thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT kailima thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT qihanli thecharacterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT jingjingzhang characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT fengyuanzeng characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT yanmeili characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT changyongmu characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT changeliu characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT lichunwang characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT xiaowupeng characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT lipinghe characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT yanruisu characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT hongbingli characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT anwang characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT linfeng characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT dongxiugao characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT zhixiaozhang characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT gangxu characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT yixuanwang characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT rongyue characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT junbosi characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT lichunzheng characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT xiongzhang characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT fuyunhe characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT hongkunyi characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT zhongshutang characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT gaocanli characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT kailima characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants
AT qihanli characterizationoftechnicaldesignofaviruslikestructurevlsnanodeliverysystemasvaccinecandidateagainstsarscov2variants